{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-193238","form_type":"8-K","ticker":"IDYA","cik":"0001676725","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2025-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.615537+00:00","generated_at":"2026-05-17T08:53:32.695220+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEAYA licenses darovasertib ex-US to Servier for $210M upfront plus milestones up to $320M","bullets":["Exclusive license to Servier for darovasertib outside the US; all human diagnostic, prophylactic, therapeutic uses.","Upfront $210M; up to $100M development/regulatory milestones and $220M commercial milestones.","Royalties on ex-US net sales: mid-teens to low-twenties percent.","Cash runway extended by at least 12 months; expects funding into 2030 under current plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-193238","json":"https://secwatch.observer/filing/0001193125-25-193238.json","markdown":"https://secwatch.observer/filing/0001193125-25-193238.md","text":"https://secwatch.observer/filing/0001193125-25-193238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/0001193125-25-193238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312525193238/d800731d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:53:32.695220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}